{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:50:25Z","timestamp":1792219825504,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ophtha.2004.11.030","type":"journal-article","created":{"date-parts":[[2005,1,27]],"date-time":"2005-01-27T07:53:17Z","timestamp":1106812397000},"page":"366-375","source":"Crossref","is-referenced-by-count":144,"title":["Results of the European Glaucoma Prevention Study"],"prefix":"10.1016","volume":"112","member":"78","reference":[{"key":"10.1016\/j.ophtha.2004.11.030_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0002-9394(89)90423-6","article-title":"Glaucoma: the damage caused by pressure","volume":"108","author":"Anderson","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib2","series-title":"Preferred Practice Pattern. Primary Open-Angle Glaucoma","year":"1992"},{"key":"10.1016\/j.ophtha.2004.11.030_bib3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archopht.1991.01080080050026","article-title":"Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans","volume":"109","author":"Sommer","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archopht.1995.01100020100038","article-title":"Hypertension, perfusion pressure, and primary open angle glaucoma","volume":"113","author":"Tielsch","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archopht.1995.01100070092031","article-title":"Risk factors for open-angle glaucoma","volume":"113","author":"Leske","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archopht.1994.01090130079022","article-title":"Family history and risk of primary open angle glaucoma","volume":"112","author":"Tielsch","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0161-6420(00)00138-X","article-title":"Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study","volume":"107","author":"Bonomi","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1755-3768.1993.tb04989.x","article-title":"Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open-angle glaucoma","volume":"71","author":"Ekstrom","year":"1993","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib9","doi-asserted-by":"crossref","unstructured":"Kass MA, Heuer DK, Higginbotham EJ et al, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. A randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701\u201313.","DOI":"10.1001\/archopht.120.6.701"},{"key":"10.1016\/j.ophtha.2004.11.030_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0161-6420(89)32688-1","article-title":"A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects","volume":"96","author":"Epstein","year":"1989","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib11","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/archopht.1989.01070020668025","article-title":"Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals","volume":"107","author":"Kass","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0161-6420(91)32296-6","article-title":"A comparison of treated and untreated glaucoma suspects","volume":"98","author":"Schulzer","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0149-2918(00)88478-7","article-title":"Antiglaucoma medications: a review of safety and tolerability issues related to their use","volume":"22","author":"Schuman","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.ophtha.2004.11.030_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1350-9462(99)00006-3","article-title":"Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors","volume":"19","author":"Sugrue","year":"2000","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2004.11.030_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0039-6257(97)00053-2","article-title":"Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor","volume":"42","author":"Pfeiffer","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00061198-199812000-00007","article-title":"Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine","volume":"7","author":"Adamsons","year":"1998","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ophtha.2004.11.030_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/archinte.158.3.221","article-title":"Beta-blocker-induced complications and the patient with glaucoma","volume":"158","author":"Stewart","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ophtha.2004.11.030_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archopht.1995.01100080061030","article-title":"A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol","volume":"113","author":"Strahlman","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib19","doi-asserted-by":"crossref","unstructured":"Rusk C, Sharpe E, Laurence J, et al, Dorzolamide Comparison Study Group. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin Ther 1998;20:454\u201366.","DOI":"10.1016\/S0149-2918(98)80055-6"},{"key":"10.1016\/j.ophtha.2004.11.030_bib20","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0161-6420(02)01167-3","article-title":"The European Glaucoma Prevention Study design and baseline description of the participants","volume":"109","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0161-6420(02)01754-2","article-title":"Reproducibility of evaluation of optic disc change for glaucoma with stereo optic disc photographs","volume":"110","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib22","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0161-6420(01)00760-6","article-title":"Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS)","volume":"108","author":"Brandt","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0197-2456(00)00042-8","article-title":"A quantifiable alternative to double data entry","volume":"21","author":"King","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ophtha.2004.11.030_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/sim.4780010204","article-title":"Tables of the number of patients required in clinical trials using the logrank test","volume":"1","author":"Freedman","year":"1982","journal-title":"Stat Med"},{"key":"10.1016\/j.ophtha.2004.11.030_bib25","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1001\/archopht.1980.01020041015002","article-title":"Biostatistical analysis of the Collaborative Glaucoma Study","volume":"98","author":"Armaly","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib26","doi-asserted-by":"crossref","unstructured":"Heijl A, Leske MC, Bengtsson B, et al, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268\u201379.","DOI":"10.1001\/archopht.120.10.1268"},{"key":"10.1016\/j.ophtha.2004.11.030_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archopht.1993.01090010100034","article-title":"Randomized clinical trials on medical treatment of glaucoma","volume":"111","author":"Rossetti","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib28","doi-asserted-by":"crossref","unstructured":"Gordon MO, Beiser JA, Brandt JD, et al, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714\u201320.","DOI":"10.1001\/archopht.120.6.714"},{"key":"10.1016\/j.ophtha.2004.11.030_bib29","doi-asserted-by":"crossref","unstructured":"Leske MC, Heijl A, Hussein M, et al, Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48\u201356.","DOI":"10.1001\/archopht.121.1.48"},{"key":"10.1016\/j.ophtha.2004.11.030_bib30","unstructured":"Pockock SJ. Sperimentazioni Cliniche. Approccio Pratico [Clinical Trials. A Practical Approach]. Torino, Italy: Centro Scientifico Torinese; 1989:91\u2013100."},{"key":"10.1016\/j.ophtha.2004.11.030_bib31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9394(98)00095-6","article-title":"Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension","volume":"126","author":"Silver","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib32","series-title":"Terminology and Guidelines for Glaucoma","year":"2003"},{"key":"10.1016\/j.ophtha.2004.11.030_bib33","doi-asserted-by":"crossref","unstructured":"Orengo-Nania S, Landry T, Von Tress M, et al, Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001;132:860\u20138.","DOI":"10.1016\/S0002-9394(01)01257-0"},{"key":"10.1016\/j.ophtha.2004.11.030_bib34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0002-9394(14)72009-4","article-title":"A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension","volume":"122","author":"Strahlman","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib35","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0161-6420(99)90497-9","article-title":"Early Manifest Glaucoma Trial: design and baseline data","volume":"106","author":"Leske","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s004170000189","article-title":"Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial","volume":"238","author":"Heijl","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00417-002-0614-4","article-title":"Results of the betaxolol versus placebo treatment trial in the ocular hypertension","volume":"241","author":"Kamal","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2004.11.030_bib40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0161-6420(99)90147-1","article-title":"The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients","volume":"106","author":"Musch","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2004.11.030_bib41","doi-asserted-by":"crossref","unstructured":"Lichter PR, Musch DC, Gillespie BW, et al, CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943\u201353.","DOI":"10.1016\/S0161-6420(01)00873-9"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642004017865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642004017865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T21:55:30Z","timestamp":1548798930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642004017865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0161642004017865"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2004.11.030","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}